NCT01340729 - Open-Label Study of TPI 287 for Patients With Metastatic Melanoma | Biotech Hunter

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2016

Conditions

Metastatic Melanoma

Interventions

DRUG

TPI 287

Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston